Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The vascular endothelial growth factor receptor (VEGFR) tyrosine kinase family comprises cell surface receptors crucial for angiogenesis, vasculogenesis, and lymphangiogenesis. Activation by VEGF ligands triggers dimerization and autophosphorylation, initiating downstream signaling pathways involved in cell proliferation, migration, survival, and vascular permeability. The family includes VEGFR-1 (FLT-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt4), each with distinct ligand specificities and biological functions. Dysregulation is implicated in cancer, making them therapeutic targets for antiangiogenic therapies.
Tyrosine kinase inhibition, Ligand sequestration
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Family (VEGFR family).